Insmed Inc’s recently made public that its Chief People Strategy Officer Schaeffer Orlov S Nicole unloaded Company’s shares for reported $11.13 million on Sep 12 ’25. In the deal valued at $145.45 per share,76,520 shares were sold. As a result of this transaction, Schaeffer Orlov S Nicole now holds 36,461 shares worth roughly $6.91 million.
Then, SHAROKY MELVIN MD sold 10,000 shares, generating $1,453,900 in total proceeds. Upon selling the shares at $145.39, the Director now owns 262,675 shares.
Before that, Schaeffer Orlov S Nicole bought 76,520 shares. Insmed Inc shares valued at $11,127,662 were divested by the Officer at a price of $145.42 per share.
A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in mid October with a ‘”an Overweight”‘ rating. William Blair began covering INSM with “an Outperform” recommendation on August 20, 2025. Morgan Stanley revised its rating on August 13, 2025. It rated INSM as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock fall -2.38% to $189.6. Over the last five days, the stock has gained 18.75%. Insmed Inc shares have risen nearly 167.23% since the year began. Nevertheless, the stocks have risen 174.62% over the past one year. While a 52-week high of $194.70 was reached on 10/31/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 185.39, which if violated will result in even more drops to 181.17. On the upside, there is a resistance level at 195.45. A further resistance level may holdings at 201.29.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-10-15, dropping by -1.09 million shares to a total of 9.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 10.58 million shares. There was a decline of -11.54%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 13, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $105 price target.
